TOPLINE:
The chikungunya virus virus-like particle (CHIKV VLP) vaccine achieved 100% seroconversion in adults who had previously received alphavirus vaccines and alphavirus vaccine–naive control individuals, with the previous recipients showing a faster immune response. Moreover, both groups had similar safety profiles.
METHODOLOGY:
- Researchers conducted an open-label, phase 2, randomized controlled trial at two clinical sites in the United States to assess the immunogenicity and safety of CHIKV VLP among previous recipients of alphavirus vaccines and alphavirus vaccine–naive control individuals.
- They enrolled 60 participants (median age, 47 years; 33% women), of whom 30 were previous recipients of alphavirus vaccines and 30 were age- and sex-matched alphavirus vaccine–naive control individuals.
- The study included a…